Knowledge spotlight potential for brand spanking new diagnostics and therapeutics concentrating on purple meat allergy
SOUTH SAN FRANCISCO, Calif. – Feb. 10, 2025 – IgGenix, Inc., a clinical-stage biotechnology firm pioneering modern therapies for immune-mediated illnesses, at present introduced the upcoming presentation of latest information on the 2025 American Academy of Allergy, Bronchial asthma & Immunology (AAAAI) / World Allergy Group (WAO) Joint Congress, to be held February 28 – March 3, 2025, in San Diego, California. The information showcase the invention of alpha-gal-specific monoclonal antibodies (mAbs) from purple meat-allergic people, marking an development within the understanding of Alpha-gal Syndrome (AGS), often known as purple meat allergy.
“Alpha-gal Syndrome is a posh situation that disrupts day by day life for these affected, and understanding its mechanisms is essential to addressing the impression,” stated Jessica Grossman, MD, CEO of IgGenix. “This discovery is a significant step ahead, providing new insights into AGS and broader immune responses that would result in breakthrough therapies on this and different immune-mediated situations.”
Little is understood in regards to the properties of mAbs underlying AGS in people because of the technical issue of isolating uncommon single B cells that produce alpha-gal-specific mAbs. Utilizing its proprietary SEQ SIFTER™ platform, IgGenix found greater than 60 mAbs from a number of purple meat-allergic people. These antibodies exhibited a slender binding affinity vary regardless of numerous variable area gene utilization and antibody affinity maturation, suggesting molecular mechanisms that distinguish AGS from canonical meals protein allergen hypersensitivity. Clonal households of comparable antibodies exhibited persistence over time, suggesting mechanisms underpinning immunological reminiscence in AGS.
Presentation Particulars
- Summary Title: Alpha-gal Particular Monoclonal Antibodies Found from Pink Meat Allergic People
- Poster Quantity: 843
- Session Title: Novel Genes and Biomarkers of Allergic Illness
- Session Kind: Poster Session
- Session Date/Time: Sunday, March 2, 9:45 am – 10:45 am
About IgGenix
IgGenix is a privately held antibody discovery and improvement firm taking a revolutionary strategy to immediately deal with allergic reactions and atopic illnesses. By our proprietary SEQ SIFTER™ discovery platform, developed from foundational analysis of co-founders Stephen Quake, Kari Nadeau, and Derek Croote of Stanford College, we isolate and re-engineer totally human, high-affinity, allergen-specific antibodies designed to dam and stop the allergic cascade. By concentrating on widespread immunodominant allergens and their most necessary epitopes throughout the affected person inhabitants, we intend to deal with allergic pediatric and grownup sufferers alike throughout meals and environmental allergic reactions. This novel strategy might stop life-threatening allergic reactions, saving lives and lowering the fixed worry that impacts thousands and thousands of individuals dwelling with extreme allergic reactions.
Contact
For Investor Inquiries:
Jessica Grossman
jgrossman@iggenix.com
